Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
| Autor: | Pedro Martínez-Romero, Sara Blasco-Turrión, Eduardo Martínez-Morentín, Carmen Collado-Moreno, Pilar Caro-Mateo, Francisco J. Morales-Ponce, Juan Antonio Sánchez-Brotons, Pablo J. González-Pérez |
|---|---|
| Přispěvatelé: | Medicina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Percutaneous Abciximab MEDLINE Myocardial Infarction Tenecteplase Clinical Cardiology Immunoglobulin Fab Fragments Text mining Fibrinolytic Agents Internal medicine Intervention (counseling) medicine Humans Ventricular Function Myocardial infarction cardiovascular diseases Ventricular function business.industry General Medicine medicine.disease Treatment Outcome Cardiology Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Cardiology Journal 2021, Vol. 28, No. 1, 176–178 RODIN: Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz Universidad de Cádiz Cardiol J RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz instname |
| Popis: | Adjunctive medical therapy during primary percutaneous coronary intervention (PPCI) is based on anticoagulation and antiplatelet drugs. Additionally, the glycoprotein IIb/IIIa inhibitor (GPI) abciximab has been shown to reduce infarct size in some clinical trials [1]. However, the role of intracoronary fibrinolysis has not been well established during PPCI. We sought to explore the hypothesis that a locally administered fibrinolytic could be more effective in dissolving coronary thrombus at the macro and microvasculature than adding a third antiplatelet drug in patients already receiving double antiplatelet therapy, and therefore improve myocardial perfusion and left ventricular function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|